Clinical manifestation of macrolide antibiotic toxicity in CKD and dialysis patients

Terry King-Wing Ma, Kai-Ming Chow, Agnes Shin Man Choy, Bonnie Ching-Ha Kwan, Cheuk-Chun Szeto and Philip Kam-Tao Li

Carol and Richard Yu Peritoneal Dialysis Research Centre, Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China

Correspondence and offprint requests to: Chow Kai Ming; E-mail: Chow_Kai_Ming@alumni.cuhk.net

Abstract

Macrolide antibiotics, erythromycin, clarithromycin and azithromycin are commonly prescribed for upper respiratory infection, and their use has recently been further linked to immunomodulatory effects. With the widespread and expanded use of macrolides, special attention should be paid to their potential adverse effects. We reported two cases of end-stage renal disease (ESRD) patients who developed hallucinations such as vivid images of worms after taking clarithromycin. Similar to previous case reports of clarithromycin neurotoxicity, the visual hallucination resolved upon cessation of clarithromycin. Furthermore, we discussed the pharmacokinetic properties and other toxicities of macrolide antibiotics in patients with chronic kidney disease and ESRD.

Keywords: azithromycin; clarithromycin; colchicine; neurotoxicity; peritoneal dialysis

Introduction

In the past decade, macrolide antibiotics have been increasingly prescribed, and more so for the treatment of community-acquired respiratory tract infection. The recent interest of macrolides linked to its anti-inflammatory effect on airway diseases (notably obstructive airway disease and non-cystic fibrosis bronchiectasis) has brought renewed attention to this class of drugs [1–3]. The prototype macrolide erythromycin has been used since 1952; other commonly used macrolides include clarithromycin and azithromycin. Despite their difference in pharmacologic properties and chemical structures, the three macrolide antibiotics share similar adverse event profiles. Some of the macrolide toxicities are of particular concern among patients with chronic kidney disease.

This in-focus review of macrolide toxicity covers those that have more significant clinical manifestation of chronic kidney disease patients, including those on dialysis. Patients who are at risk of or who have known kidney disease are also included in the discussion.

Drug properties of macrolides

As a class, macrolides act via the same mechanism, namely, binding to the 50S subunit of the bacterial ribosome and blocking initiation of protein synthesis [4]. They all consist of a large lactone ring. Erythromycin and clarithromycin have 14-membered lactone ring, whereas azithromycin has a 15-membered ring. Minor structural changes prevent the metabolism of clarithromycin and azithromycin to an inactive compound, improve the acid stability, and provide a broader spectrum of antibacterial activity than erythromycin.

Erythromycin is metabolized by cytochrome P450 (CYP) enzyme CYP3A4 and eliminated primarily by faeces. Since only a small fraction (less than 7.5%) appears in urine as unchanged drug [5], kidney disease has theoretically minimal impact on the pharmacokinetics of erythromycin. However, clinical observation of elevated serum erythromycin concentrations and prolonged half-life in patients with end-stage renal disease (ESRD), associated with reversible hearing loss, led to speculation of altered drug clearance [6, 7]. These results have important clinical implications on drug dosing of erythromycin in ESRD patients. It is now believed that hepatic CYP3A4 metabolic activity, one of the most important enzymes in human drug metabolism, is decreased in uraemia and acutely improved by haemodialysis therapy. Specifically, CYP3A4 activity and elimination of erythromycin is increased by 27% after 2 h of conventional haemodialysis, presumably via removal of a rapid-acting and dialyzable byproduct of uraemia that can inhibit hepatic intrinsic clearance mediated by CYP3A4 [8]. A mounting body of experimental and clinical evidence indicates altered nonrenal clearance, namely, impaired hepatic clearance, of erythromycin in ESRD patients. Reduced hepatic clearance is attributed to downregulation of cytochrome P450 enzymes and
alterations in the transporter system (of drugs into or out of the liver) [9, 10]. Clarithromycin is metabolized by CYP 3A4 to its 14-hydroxy active metabolite, both of which require renal excretion [11]. Because the metabolite 14-hydroxy derivative is primarily excreted in the urine, an increase in area under the plasma concentration-time curve, peak plasma concentrations and elimination half-life are expected in patients with kidney disease (but not those with hepatic impairment). The need to adjust clarithromycin dose for patients with kidney disease is supported by pharmacokinetic studies showing a prolonged elimination half-life of clarithromycin and its metabolite 14-hydroxyclarithromycin when the creatinine clearance is <30 mL/min [11, 12]. Clarithromycin has high lipid solubility which renders it poorly dialyzable.

Azithromycin is excreted in bile and then faeces. Unlike clarithromycin, very little unchanged azithromycin appears in the urine, and there are no biologically active metabolites. Thus, azithromycin dosing modification is not needed in patients with kidney disease. It is also not substantially removed by peritoneal dialysis [13].

**Neurotoxicity of macrolides**

Antibiotic-induced neurotoxicity is a well-known complication in patients with chronic kidney disease and ESRD. Common examples include penicillins, cephalosporins, carbapenems and quinolones [14, 15]. Clarithromycin [16], and much less for erythromycin [17, 18], have been reported to cause neurotoxicity, mostly in the form of acute delirium or psychosis. Although uncommon, visual hallucination was the predominant presenting symptom of clarithromycin-induced neurotoxicity in some patients, including both dialysis [19, 20] and non-dialysis populations [21, 22]. Most patients improved spontaneously upon cessation of clarithromycin. Box 1 and Box 2 outline two patients with ESRD and clarithromycin neurotoxicity.

**Box 1.** A 55-year-old male patient suffered from ESRD secondary to hypertensive nephrosclerosis and was started on continuous ambulatory peritoneal dialysis (CAPD) for 5 years. He was admitted to hospital because of a history of insomnia, tinnitus and visual hallucination for 3 days. He reported seeing worms crawling in his surrounding environment, rendering him unable to perform CAPD. Five days before admission, he was diagnosed to have *Helicobacter pylori*-related gastritis and started on amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily and esomeprazole 20 mg twice daily. Concurrent medications included allopurinol, atenolol, nifedipine sustained release, spironolactone and calcium carbonate. He had no focal neurological deficit or fever. Computed tomography of the brain and electrolytes were unremarkable. He was managed conservatively and symptoms completely subsided after 4 days. There was no recurrence of symptoms in the subsequent 7 years of follow-up. Causality assessment of adverse drug reaction suggested possible (Naranjo probability scale score 4) clarithromycin toxicity; we cannot exclude the alternative explanation by the concurrent use of relatively high-dose amoxicillin.

**Box 2.** A 71-year-old female patient had ESRD due to IgA nephropathy, for which she had received dialysis treatment for >20 years. Due to progressive cognitive impairment, she required assisted CAPD by a domestic helper. Other medical comorbidities included bilateral cataract, ischaemic heart disease and atrial fibrillation.

Three weeks before admission, she was admitted to hospital because of CAPD peritonitis due to coagulase-negative staphylococcus and *Moraxella catarrhais*. She was initially treated with intraperitoneal cefazolin and ceftazidime, without clinical response. Antibiotic regime was switched to intraperitoneal vancomycin 1 g once every 5 days and oral clarithromycin 250 mg twice daily was added to cover *Moraxella* infection based on sensitivity results. She responded well with that regime. Her other medications included aspirin, famotidine, bisoprolol, isosorbide dinitrate, valsartan, alfacalcidol and nystatin. She developed unsteady gait after 10 days of clarithromycin. She then reported seeing worms over her body and in her surrounding environment after 16 days of clarithromycin. She was subsequently admitted to hospital because of a fall, minor head injury and scalp laceration. She had no focal neurological deficit or cerebellar signs. Computed tomography of the brain showed cerebral atrophy but no evidence of acute stroke. Electrolytes were unremarkable. Clarithromycin was stopped and symptoms completely subsided after 1 week. She had no recurrence of symptoms in her subsequent follow-up and remained well on CAPD. Naranjo criteria suggested probable clarithromycin adverse event (score 7).

Steinman and Steinman [19] first reported clarithromycin-induced visual hallucination in a 56-year-old ESRD patient on CAPD. The patient had acute onset of visual hallucination within 24 h after taking clarithromycin 500 mg twice daily for acute bronchitis. His visual hallucination was described as a ‘constantly evolving landscape of sharks, priests, red lines and other Technicolor parasites’ that gradually evolved over 3 weeks. Similarly, both of our patients had visual hallucination in the form of parasitosis.

The mechanism of clarithromycin-induced neurotoxicity remains largely unknown. Proposed neurotoxicity mechanisms include direct toxicity of the lipid-soluble active metabolite of 14-hydroxycarboxy, clarithromycin on the central nervous system, alterations of cortisol and prostaglandin metabolism, inhibitory action on glutaminergic neurotransmission [23].

In our second patient (Box 2) who received a reduced dose of clarithromycin, neurotoxicity developed after 10 days. This might reflect the gradual accumulation of clarithromycin and its metabolite even with adjusted dose. Of note, our second patient had been anuric for years and had no residual renal function. Altered blood–brain barrier in the setting of uraemia may be associated with increased concentration of clarithromycin and its metabolite in the central nervous system, which may be another contributing factor in the development of neurotoxicity.
Macrolide toxicity and renal disease

Bandettini et al. [16] analysed 38 patients who developed neurotoxicity after clarithromycin. Most patients had a history of psychiatric illness and only 2 patients had renal insufficiency. This implies that elevated serum drug level secondary to reduced renal excretion is only one possible mechanism of neurotoxicity. In fact, hallucination had been reported in patients taking therapeutic doses of clarithromycin [21, 22]. Clarithromycin has been linked to the development of many acute psychotic manifestations, including the phenomenon of ‘antibiomania’, the feeling of ‘leaving the planet’, and cat-like screeching and movements [24]. According to previous World Health Organization and the Food and Drug Administration, clarithromycin and ciprofloxacin are the most frequent causes linked to antibiotic-induced manic episodes or antibiomania [23]. Other neurotoxic manifestations of clarithromycin include non-convulsive status epilepticus, depersonalization, semicatatonic behaviour, paranoid ideation, delirium and insomnia [16, 25–29]. On the other hand, prolonged duration of treatment may not necessarily result in neurotoxicity. In two series of atypical mycobacterium exit site infection in peritoneal dialysis patients, 10 out of 15 patients received prolonged clarithromycin therapy ranging from 6 to 42 weeks. None of them developed neurotoxicity, although the exact dosages of clarithromycin were not mentioned in either study [30, 31].

Cardiotoxicity of macrolides

All three macrolides, erythromycin, clarithromycin and azithromycin, have been associated with QT interval prolongation. The single most important concern with drug-induced QT prolongation is risk of fatal polymorphic ventricular tachycardia, or torsades de pointes (characterized by QRS complexes of progressively changing amplitude and contour that seem to twist around the isoelectric line from beat to beat).

The mechanism of QT prolongation after macrolides is blockage of the outward potassium current or channel in myocyte membranes [32]. Although QT interval lengthening is not infrequent after clarithromycin, reports of torsades de pointes after clarithromycin appear to be primarily linked to simultaneous administration of other drugs that prolong the QT interval. Analysis of torsades de pointes associated with macrolide also highlighted the risk factors of concomitant drugs, female gender and increasing age [33]. At least three case reports of torsades de pointes after clarithromycin have been published in patients with creatinine clearance below 30 mL/min when they received clarithromycin at 500 mg twice daily [34, 35]. Such an observation implies the dose effectness of clarithromycin, which can accumulate to the high-risk level in the presence of renal failure (when the dose is not adjusted accordingly). Similarly, a dose-response effect of erythromycin has been reported; the effect on the QT interval is directly related to the rate of intravenous infusion of erythromycin [36]. Azithromycin metabolism is not affected by kidney function. For unknown reasons, on the other hand, acute kidney injury has been suggested to be a risk factor for azithromycin-induced torsades de pointes [37].

The observation that prolonged QT interval increased the all-cause mortality and the risk of sudden cardiac death in ESRD patients [38, 39] suggests the possibility of a further increased propensity to macrolide cardiac toxicity in this population.

Indirect kidney injury after macrolides

Macrolides do not cause direct nephrotoxicity in general [40], but erythromycin and clarithromycin can influence kidney function secondary to interactions with other drugs. These two macrolides are strong inhibitors of CYP3A4 enzymes, and thus lead to accumulation of drugs that require CYP3A4 for their metabolism, potentially causing toxicity. In other words, the potential mechanisms whereby macrolides are linked to adverse kidney events are the indirect effect of increased concentration of concurrent drugs such as statins and calcium-channel blockers.

A recent Canadian population-based cohort study involving 144,336 users of erythromycin, clarithromycin or azithromycin together with statins found a 2-fold increased risk of hospitalization (relative risk 2.17, 95% CI 1.04–4.53) with rhabdomyolysis among those taking statin and coprescription of erythromycin or clarithromycin [41]. The absolute risk increase was 0.02%, 95% CI 0.01–0.03%. The results also confirmed an increased risk of hospitalization with acute kidney injury, hyperkalaemia and all-cause mortality after concurrent use of statins with erythromycin or clarithromycin. This study evaluated statins (atorvastatin, simvastatin or lovastatin) metabolized by CYP3A4 isoenzyme, and confirmed a significantly lower risk of myopathy with concurrent use of azithromycin which does not inhibit CYP3A4. Although only older adults (older than 65 years) were included in the study, it appears prudent to consider a different antibiotic or temporarily stop the CYP3A4–metabolized statin during erythromycin or clarithromycin administration in all patients [41, 42]. Current warnings and recommendations are avoidance of lovastatin and simvastatin with erythromycin or clarithromycin, whereas atorvastatin dose adjustment may be required. Increased monitoring for toxicity is warranted for any such combination.

A much less commonly recognized mechanism by which clarithromycin may cause kidney injury indirectly is via an increase in concentrations of calcium-channel blockers and thus hypotensive insult to the kidneys. This has been shown by two Canadian groups evaluating the use of macrolide and calcium-channel blocker in elderly subjects [43, 44]. The first signal of hypotension risk came from a population-based nested, case–crossover study that included patients who required hospital admission for the treatment of shock or hypotension within 7 days after co-prescription of macrolide antibiotics and calcium-channel blockers (amlodipine, felodipine, nifedipine, verapamil, diltiazem, all of them being metabolized by CYP3A4 enzyme) [43]. This study did not look into nephrotoxicity but confirmed the strongest association of hypotension with concurrent erythromycin (the strongest inhibitor of CYP3A4), followed by clarithromycin. No such association with azithromycin was reported [43]. The second population-based cohort study studied concurrent use of clarithromycin and the previously mentioned calcium-channel blockers [44]. Using azithromycin as a comparator to minimize confounding by indication, the population-based cohort study showed a small but statistically significant greater 30-day risk of hospitalization with acute kidney injury (absolute risk increase 0.22%, 95% CI 0.16–0.27%). The risks of hospitalization with hypotension and all-cause mortality were both increased. The most pronounced effect was observed with concurrent use of clarithromycin and nifedipine [44]. Collectively, these studies indicate a small but significant risk of
combined use of macrolide and calcium-channel blockers among older patients. What are the implications for patients with chronic kidney disease? We suspect chronic kidney disease patients represent another at-risk group given the widespread use of calcium-channel blockers among them and the susceptibility of the injured kidney to hypotensive insults. Nevertheless, this needs to be substantiated in further analysis because <10% of the subjects were suffering from chronic kidney disease in the two Canadian studies [43, 44].

**Drug toxicity after macrolides interaction**

In addition to the inhibition of CYP3A4 enzyme, macrolides are also known to inhibit the P-glycoprotein transport system [45]. P-glycoprotein, also known as multidrug transporter 1 and ATP-binding cassette B1 transporter, is located in the apical membrane of the enterocytes and functions as the intestinal drug efflux pump, reducing the absorption of orally administered drugs [46]. Consequently, P-glycoprotein inhibitor may increase the bioavailability of those drugs which are substrate for the P-glycoprotein transport system. P-glycoprotein is also present on the canalicular aspect of the hepatocyte (biliary excretion), as well as an important component of the blood–brain barrier.

Two clinically important P-glycoprotein substrates relevant to kidney disease are colchicine and digoxin. Colchicine is not uncommonly used in patients with chronic kidney disease and acute gout, when nonsteroidal anti-inflammatory drugs are considered undesirable. Ten per cent or more of colchicines undergoes excretion by the kidneys, besides the metabolism by the cytochrome P450 system. Colchicine accumulation occurs in patients with renal or hepatic dysfunction, and even more so when there is concomitant use of erythromycin or clarithromycin (both renal or hepatic dysfunction, and even more so when there is given the widespread use of calcium-channel blockers among them and the susceptibility of the injured kidney to hypotensive insults. Nevertheless, this needs to be substantiated in further analysis because <10% of the subjects were suffering from chronic kidney disease in the two Canadian studies [43, 44].

**Box 3.** An 85-year-old elderly with chronic kidney disease, diabetes and gout was admitted from an aged care home for symptomatic anaemia. Her estimated glomerular filtration rate was 28 mL/min/1.73 m² and haemoglobin level was low (7.7 g/dL). An upper endoscopy showed mild gastritis and Helicobacter pylori. She was transfused and given eradication therapy which included clarithromycin 500 mg twice daily. Three days later, she developed acute gouty arthritis and was treated with oral colchicine 0.5 mg four times daily. Four days after colchicine use, her platelet count decreased from 230 to 127 ×10⁹/L. She developed sudden cardiac arrest 2 days afterward, when her complete blood count showed a platelet count of 32 ×10⁹/L and white cell count 0.8 ×10⁹/L.

A retrospective analysis of 116 Chinese patients who were prescribed colchicine and clarithromycin during the same hospital admission confirmed a high risk of fatalities (10.2%). Independent predictors of death were renal impairment (defined as serum creatinine level above 140 µmol/L at baseline), longer overlapping therapy of colchicine and clarithromycin, and the development of pancytopenia [47]. Reported manifestations of colchicine toxicity with concurrent clarithromycin include haematological (pancytopenia, hypocellular bone marrow), gastrointestinal (vomiting, diarrhoea, abdominal pain), neuromyopathy (including rhabdomyolysis), multi-organ dysfunction and death [47, 48]. Although a specific recommendation for colchicine dose reduction (when macrolide such as clarithromycin is coprescribed) has been published [49], the safeguards need to be substantiated in large clinical trials. In this regard, avoiding combined use of colchicine and P-glycoprotein inhibitor remains the best strategy to prevent drug interaction, and especially among patients with chronic kidney disease.

Digoxin toxicity after macrolide use in patients with chronic kidney disease or ESRD has been characterized more in the literature [50, 51], and continues to be one of the most prevalent adverse drug reactions in clinical practice. This should come as no surprise after considering the pharmacokinetics of digoxin. Over 70% of the body load of digoxin is eliminated unchanged in the urine. Furthermore, patients with chronic kidney disease have decreased extra-vascular volume of digoxin distribution. These account for the prolonged half-life of digoxin in patients with chronic kidney disease, as well as the need to reduce the loading and maintenance digoxin dose. When macrolides (erythromycin, clarithromycin and azithromycin) are administered together with digoxin, the inhibition of P-glycoprotein will further increase the digoxin levels because digoxin is a substrate for P-glycoprotein.

A study comparing digoxin concentration before and (four to seven days) after clarithromycin treatment in seven elderly found that digoxin level increased significantly; the digoxin clearance and elimination rate constants were 56–60% lower and elimination half-life was 82% longer [52]. Moreover, only one out of the seven patients developed an electrocardiographic sign of digoxin toxicity when she developed acute kidney injury, which further reduced the digoxin clearance [52].

The observation is consistent with the finding of a 15-year population-based nested case-control study evaluating digoxin toxicity after recent macrolide antibiotic use. Indeed, the risk of digoxin toxicity is highest for recent use of clarithromycin (adjusted odds ratio 14.83, 95% CI 7.89–27.86), followed by erythromycin and azithromycin. There was no significant risk for the neutral comparator of cefuroxime [53]. The risk of digoxin toxicity after clarithromycin is 4-fold higher than erythromycin or azithromycin. This is consistent with in vitro data showing the highest inhibitory capacity of P-glycoprotein for clarithromycin [45]. Thus, it should be emphasized that use of azithromycin might avoid drug interaction via CYP3A4, but azithromycin might still lead to clinically important drug interaction (such as digoxin) by inhibiting P-glycoprotein [54]. Risk of concomitant use of macrolide with digoxin also applies to ESRD patients. Specifically, adding clarithromycin to six ESRD patients taking oral digoxin (on haemodialysis or haemofiltration) was shown to cause 1.8–4.0-fold increase in their serum digoxin levels [51].

Another potential and interesting mechanism of drug interaction between macrolide and digoxin is mediated by human intestinal bacteria. There is evidence that inactivation of digoxin by the gut actinobacterium Eggerthella lenta to its inactive metabolite, dihydrodigoxin, contributes to around 10% of digoxin metabolism [55, 56]. Macrolides including azithromycin can kill off a large fraction of Eggerthella lenta bacteria and therefore increase the serum digoxin concentration.
Table 1. Summary of three macrolides with reference to kidney disease

|               | Erythromycin | Clarithromycin | Azithromycin |
|---------------|--------------|----------------|--------------|
| Kidney excretion | Minimal (<7.5% unchanged in urine) | Active metabolites excreted unchanged in urine | Minimal |
| Recommended dose reduction with kidney disease | No need for dose adjustment but altered nonrenal clearance suggested in ESRD | Decrease by 50% if creatinine clearance <30 mL/min | No need for dose adjustment |
| Dialyzable | Slightly (5% to 20%) | Minimal | Minimal |
| CYP3A4 inhibition | +++ | +++ | ++++ |
| P-glycoprotein inhibition | + | ++++ | + |
| Reported neurotoxicity | + | ++ | – |

Conclusion

The mode of action is similar for all macrolides, but their pharmacokinetics and adverse events differ slightly, as summarized in Table 1. Patients with chronic kidney disease and ESRD are prone to drug-induced neurotoxicity. In particular, visual hallucination in the form of parasitosis should raise the clinical suspicion of clarithromycin neurotoxicity. Drug interaction with statins, calcium-channel blockers and colchicine is another concerning complication of macrolides. Close monitoring is warranted, and even more so in the setting of chronic kidney disease, ESRD or acute kidney injury.

Conflict of interest statement. None declared.

References

1. Albert RK, Connett J, Bailey WC et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365: 689–698
2. Brusselle GG, Joos G. Is there a role for macrolides in severe asthma? Curr Opin Pulm Med 2014; 20: 95–102
3. Serisier DJ, Martin ML, McGuickin MA et al. Effect of long-term, low-dose erythromycin on pulmonary fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013; 309: 1260–1267
4. Jain R, Donziger LH. The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr Pharm Des 2004; 10: 3045–3053
5. Disse B, Gundert-Remy U, Weber E et al. Pharmacokinetics of erythromycin in patients with different degrees of renal impairment. Int J Clin Pharmacol Ther Toxicol 1986; 24: 460–464
6. Kroboth PD, McNeil MA, Kreeger A et al. Hearing loss and erythromycin pharmacokinetics in a patient receiving hemodialysis. Arch Intern Med 1983; 143: 1263–1265
7. Taylor R, Schofield IS, Ramos JM et al. Ototoxicity of erythromycin in peritoneal dialysis patients. Lancet 1981; 2: 935–936
8. Nolin TD, Appiah K, Kendrick SA et al. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol 2006; 17: 2363–2367
9. Leblond F, Guévin C, Demers C et al. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 2001; 12: 326–332
10. Sun H, Frassetto LA, Huang Y et al. Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease. Clin Pharmacol Ther 2010; 87: 465–472
11. Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet 1999; 37: 385–398
12. Fraschini F, Scaglione F, Demartini G. Clarithromycin clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 189–204
13. Kent JR, Almond MK, Dhillon S. Azithromycin: an assessment of its pharmacokinetics and therapeutic potential in CAPD. Perit Dial Int 2001; 21: 372–377
14. Chow KM, Szeto CC, Hui AC et al. Mechanisms of antibiotic neurotoxicity in renal failure. Int J Antimicrob Agents 2004; 23: 213–217
15. Zhang J, Huang C, Li H et al. Antibiotic-induced neurotoxicity in dialysis patients: a retrospective study. Ren Fail 2013; 35: 901–905
16. Bondettini di Poggio M, Anfuso S, Audenino D et al. Clarithromycin-induced neurotoxicity in adults. J Clin Neurosci 2011; 18: 313–318
17. Umstead GS, Neumann KH. Erythromycin otoxicity and acute psychotic reaction in cancer patients with hepatic dysfunction. Arch Intern Med 1986; 146: 897–899
18. Cohen IJ, Weitz R. Psychiatric complications with erythromycin. Drug Intell Clin Pharm 1981; 15: 388
19. Steinman MA, Steinman TI. Clarithromycin-associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1996; 27: 143–146
20. Tse KC, Li FK, Tang S et al. Delusion of worm infestation associated with clarithromycin in a patient on peritoneal dialysis. Perit Dial Int 2001; 21: 415–416
21. Jiménez-Pulido, Navarro-Ruiz A, Sendra P et al. Hallucinations with therapeutic doses of clarithromycin. Int J Clin Pharmacol Ther 2002; 40: 20–22
22. Erkek N, Senel S, Karacan C. Visual hallucinations possibly associated with clarithromycin administration at therapeutic dosage in two children. Med Princ Pract 2009; 18: 332–334
23. Abouesh A, Stone C, Hobbs WR. Antimicrobial-induced mania (antibiomania): a review of spontaneous reports. J Clin Psychopharmacol 2002; 22: 71–81
24. Shah M, Subhani M, Rizvon K et al. Transient psychotic episode induced by Helicobacter pylori triple therapy treatment. Case Rep Gastroenterol 2012; 6: 381–386
25. Mermanstein HT. Clarithromycin-induced delirium in a general hospital. Psychosomatics 1998; 39: 540–542
26. Warner A. Clarithromycin—a precipitant for acute psychotic stress. Psychosomatics 2000; 41: 539
27. Özsoyalar G, Sayin A, Bolay H. Clarithromycin monotherapy-induced delirium. J Antimicrob Chemother 2007; 59: 331
28. Fidän T, Fidan V. Clarithromycin-induced mania in a child. Int J Clin Pharmacol Ther 2009; 47: 402–404
29. Prime K, French P. Neuropsychiatric reaction induced by clarithromycin in a patient on high active antiretroviral therapy (HAART). Sex Transm Infect 2001; 77: 297–298
30. Lo MW, Mok SK, Wong YY et al. Atypical mycobacterial exit-site infection and peritonitis in peritoneal dialysis patients on prophylactic exit-site gentamicin cream. Perit Dial Int 2013; 33: 267–272
31. Tse KC, Lui SL, Cheng VC et al. A cluster of rapidly growing mycobacterial peritoneal dialysis catheter exit-site infections. Am J Kidney Dis 2007; 50: e1–e5
32. Drew BJ, Ackerman MJ, Funk M et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2010; 121: 1047–1060
33. Shaffer D, Singer S, Korvick J et al. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis 2002; 35: 197–200
34. Sekkarie MA. Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. Am J Kidney Dis 1997; 30: 437–439
35. Lee KL, Jim MH, Tang SC et al. QT prolongation and torsades de pointes associated with clarithromycin. Am J Med 1998; 104: 395–396
36. Mishra A, Friedman HS, Sinha AK. The effects of erythromycin on the electrocardiogram. Chest 1999; 115: 983–986
37. Kezerashvili A, Khattak H, Barsky A et al. Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. J Interv Card Electrophysiol 2007; 18: 243–246
38. Genovesi S, Rossi E, Nava M et al. A case series of chronic haemodialysis patients: mortality, sudden death, and QT interval. Europace 2013; 15: 1025–1033
39. Hage FG, de Mattos AM, Khamash H et al. QT prolongation is an independent predictor of mortality in end-stage renal disease. Clin Cardiol 2010; 33: 361–366
40. Chapelsky MC, Nix DE, Cavanaugh JC et al. Renal tubular enzyme effects of clarithromycin in comparison with gentamicin and placebo in volunteers. Drug Saf 1992; 7: 304–309
41. Patel AM, Shariff S, Bailey DG et al. Statin toxicity from macrolide antibiotic copresentation: a population-based cohort study. Ann Intern Med 2013; 158: 869–876
42. Molden E, Skovlund E, Braathen P. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors. Drug Saf 2008; 31: 587–596
43. Wright AJ, Gomes T, Mamdani MM et al. The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers. CMAJ 2011; 18: 303–307
44. Gandhi S, Fleet JL, Bailey DG et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA 2013; 310: 2544–2553
45. Eberl S, Renner B, Neubert A et al. Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet 2007; 46: 1039–1049
46. Misaka S, Müller F, Fromm MF. Clinical relevance of drug efflux pumps in the gut. Curr Opin Pharmacol 2013; 13: 847–852
47. Hung IF, Wu AK, Cheng VC et al. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clin Infect Dis 2005; 41: 291–300
48. van der Velden W, Huussen J, Ter Loak H et al. Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin. Neth J Med 2008; 66: 204–206
49. Terkeltaub RA, Forst DE, Digiacinto JL et al. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum 2011; 63: 2226–2237
50. Lee CY, Marcotte F, Giraldeau G et al. Digoxin toxicity precipitated by clarithromycin use: case presentation and concise review of the literature. Can J Cardiol 2011; 27: e15–e16
51. Hirata S, Izumi S, Furukubo T et al. Interactions between clarithromycin and digoxin in patients with end-stage renal disease. Int J Clin Pharmacol Ther 2009; 43: 30–36
52. Zapoter P, Reus S, Tello A et al. A prospective study of the clarithromycin-digoxin interaction in elderly patients. J Antimicrob Chemother 2002; 50: 601–606
53. Gomes T, Mamdani MM, Juurlink DN. Macrolide-induced digoxin toxicity: a population-based study. Clin Pharmacol Ther 2009; 86: 383–386
54. Ten Eick AP, Sallee D, Preminger T et al. Possible drug interaction between digoxin and azithromycin in a young child. Clin Drug Invest 2000; 20: 61–64
55. Lindenbaum J, Rund DG, Butler VP Jr et al. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med 1981; 305: 789–794
56. Haiser HJ, Gootenberg DB, Chatman K et al. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 2013; 341: 295–298

Received for publication: 8.7.14; Accepted in revised form: 21.8.14